Targeting treatment-resistant breast cancer stem cells with FKBPL and Its peptide derivative, AD-01, via the CD44 pathway

Clinical Cancer Research

Volumn 19, Issue 14, 2013, Pages 3881-3893

  McClements, Lana ^a   Yakkundi, Anita ^a   Papaspyropoulos, Angelos ^d   Harrison, Hannah ^c   Ablett, Matthew P ^c   Jithesh, Puthen V ^e   McKeen, Hayley D ^a   Bennett, Rachel ^a   Donley, Christopher ^a   Kissenpfennig, Adrien ^a   McIntosh, Stuart ^b   McCarthy, Helen O ^a   O'Neill, Eric ^d   Clarke, Robert B ^c   Robson, Tracy ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AD 01; ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN LIKE; GAMMA SECRETASE INHIBITOR; HERMES ANTIGEN; N [N (3,5 DIFLUOROPHENACETYL ALANYL)]PHENYLGLYCINET BUTYL ESTER; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STEM CELL; CASE REPORT; CELL RENEWAL; CONTROLLED STUDY; EX VIVO STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOPHILINS; MCF-7 CELLS; MICE; MICE, SCID; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881145625     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0595     Document Type: Article

References (47)

1. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancer after conventional therapy display mesenchymal as well as tumour-initiating features. Proc Natl Acad Sci U S A 2009;106:13820-5.
2. McKeen HD, Byrne C, Jithesh PV, Donley C, Valentine A, Yakkundi A, et al. FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy. Cancer Res 2010;70:1090-100.
3. Fillmore C, Kuperwasser C. Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res 2007;9:303-6.
4. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44(+)/CD24(-) breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006;8:R59.
5. Shipitsin M, Campbell L, Argani P, Werernowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumour heterogeneity. Cancer Cell 2007;11:259-73.
6. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44(+)/CD24(-/low) cells in breast cancer may not be associated with clinical outcome but may favour distant metastasis. Clin Cancer Res 2005;11:1154-9.
7. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu M, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-9.
8. Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 2011;104:1730-8.
9. Zielski SP, Spalding AC, Lawrence TS. Loss of tumour-initiating cell activity in cyclophosphamide treated breast xenografts. Transl Oncol 2009;3:149-52.
10. Aulmann S, Waldburger N, Penzel R, Andrulis M, Schirmacher P, Sinn HP. Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy. Hum Pathol 2010;41:574-81.
11. Tanei T, Morimoto M, Shimazu K, Kim SJ, Tanji Y, Taquchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009;15:4234-41.
12. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12:1167-74.
13. Phuc VP, Nhan LCP, Nhung TN, Nhung HT, Thuy TD, Dong VL, et al. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med 2011;9:209-2.
14. Stern R. Association between cancer and "acid mucopolysaccharides": an old concept comes of age, finally. Semin Cancer Biol 2008; 18:238-43.
15. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011;11:254-67.
16. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumour cells. J Bio Chem 2008;283:17635-51.
17. Ezeh UI, Turek PJ, Reijo RA, Clark AT. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005;104:2255-65.
18. Bourguignon LY. Hyaluronan-CD44 interaction promotes microRNA signaling and RhoGTPase activation leading to tumor progression. Small GTPases 2012;3:53-9.
19. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005;122:947-56.
20. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012;31:1354-65.
21. Robson T, Joiner MC, Wilson GD, McCullough W, Price ME, Logan I, et al. A novel human stress response-related gene with a potential role in induced radioresistance. Radiat Res 1999;152:451-61.
22. Robson T, Price ME, Moore ML, Joiner MC, McKelvey-Martin V, McKeown S, et al. Increased repair and cell survival in cells treated with DIR1 antisense oligonucleotides: implications for induced radioresistance. Int J Radiat Biol 2000;76:617-23.
23. Jascur T, Brickner H, Salles-Passador I, Barbier V, El Khissiin A, Smith B, et al. Regulation of p21 WAF1/CIP1 stability by WISp39 a Hsp90 binding TPR protein. Mol Cell 2005;17:237-49.
24. Sunnotel O, Hiripi L, Lagan K, McDaid JR, De Leon JM, Miyagawa Y, et al. Alterations in the steroid hormone receptor co-chaperone FKBPL are associated with male infertility: a case-control study. Reprod Biol Endocrinol 2010;8:22-9.
25. McKeen HD, McAlpine K, Valentine A, Quinn DJ, McClelland K, Byrne C, et al. A novel FK506-binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signalling. Endocrinology 2008;149:5724-34.
26. McKeen HD, Brennan DJ, Hegarty S, Lanigan F, Jirstrom K, Byrne C, et al. The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL. Biochem Soc Trans 2011;39:663-9.
27. Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, et al. FKBPL and Peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin Cancer Res 2011;17:1044-56.
28. Yakkundi A, McCallum L, O'Kane A, Dyer H, Worthington J, McKeen H, et al. The anti-migratory effects of FKBPL, and its peptide derivative, AD-01, regulation of CD44 and the cytoskeletal pathway. PLoS ONE 2013;8:e55075.
29. Robson T, James IF. The therapeutic and diagnostic potential ofFKBPL: a novel anticancer protein. Drug Discov Today 2012;17:544-8.
30. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010;70:709-18.
31. Shaw F, Harrison H, Spence K, Ablett M, Simões B, Farnie G, et al. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia 2012;17:111-7.
32. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007;13:3207-14.
33. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30:207-10.
34. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
35. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-13.
36. Bolderson E, Richard DJ, Zhou BB, Khanna KK. Recent advances in cancer therapy targeting proteins involved in DNA double strand break repair. Clin Cancer Res 2009;15:6314-20.
37. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-3.
38. Purow B. Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol 2012;727:305-19.
39. Tan L, Sui X, Deng H, Ding M. Holoclone forming cells from pancreatic cancer cells enrich tumour initiating cells and represent a novel model for study of cancer stem cells. PLoS ONE 2011;6:23383-93.
40. Harrison H, Simões B, Rogerson L, Howell S, Landberg G, Clarke R. Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Res 2013;15:R21.
41. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C, et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009;27:993-1005.
42. Simões BM, Piva M, Iriondo O, Comaills V, Lopez-Ruiz JA, Zabalza I, et al. Effects of estrogen on the proportion of stem cells in the breast. Breast Cancer Res Treat 2011;129:23-35.
43. Medema JP. Cancer stem cells: the challenges ahead. Nat Cell Biol 2013;15:338-44.
44. Conley SJ, Wicha MS. Angiogenic agents: fuelling cancer's hypoxic roots. Cell Cycle 2012;11:1265-6.
45. Marangoni E, Lecomte N, Durand L, De Pinieux G, Decaudin D, Chomienne C, et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer 2009;100:918-22.
46. Fly W, Earle C, Wong G, Spevac CC, Krueger K. Stem cell marker (Nanog) and Stat-3 signalling promote Micro-RNA21 expression and chemoresistance in hyaluronan/CD44 activated head and neck squamous cell carcinoma cells. Oncogene 2012; 31:149-60.
47. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signalling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2010;6:R605-15.